M. Rybak

American Journal of Health-System Pharmacy · 2019

A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom M. Rybak trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. R. Novick

Papers from M. Rybak's perspective

Ordered by how strongly the researchers M. Rybak trusts endorse each paper. Same corpus, a different order for every researcher.

  1. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. (Archives of Internal Medicine)
  2. The pharmacokinetic and pharmacodynamic properties of vancomycin. (Clinical Infectious Diseases)
  3. Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia (Journal of Clinical Microbiology)
  4. Autoinduction and signal transduction in the regulation of staphylococcal virulence (Molecular Microbiology)
  5. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. (Clinical Infectious Diseases)
  6. Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections (Clinical Pharmacokinetics)
  7. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. (Chest)
  8. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. (New England Journal of Medicine)
  9. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of… (American Journal of Health-System Pharmacy)
  10. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. (Clinical Infectious Diseases)

Their papers